Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.

News | STEMI

Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

December 15, 2022 — Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation ...

December 15, 2022

From left, Qian Ma, PhD, and Yuqing Huo, MD, PhD. Photo courtesy of Michael Holahan, Augusta University

News | Heart Failure

New Target in the Fight Against Heart Disease

December 15, 2022 — Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply your ...

December 15, 2022

Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).

News | Heart Valve Technology

Edwards Identifies Top Data Releases of 2022 that Highlight the Impacts of Aortic Stenosis Undertreatment

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

December 14, 2022

Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry

News | Atrial Fibrillation

Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

December 14, 2022 — Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of ...

December 14, 2022

Corindus, A Siemens Healthineers Company, has officially rebranded as Siemens Healthineers

News | Cardiovascular Business

Corindus, A Siemens Healthineers Company, Is Now Siemens Healthineers Endovascular Robotics

December 14, 2022 — Corindus, A Siemens Healthineers Company, has been rebranded to Siemens Healthineers Endovascular ...

December 14, 2022

Series to feature leading experts discussing the current and future trends in the carotid treatment market

News | Stents Carotid

InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

December 13, 2022

Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.

News | Structural Heart

Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

December 13, 2022

Image courtesy of Intermountain Healthcare

News | Cardiovascular Clinical Studies

Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

December 13, 2022

The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between 2022 and 2025, driven by increasing population at a risk of cardiovascular diseases.

News | Pacemakers

Global Pacemakers Market Set to Grow at 5.4% CAGR Over Next 3 Years

December 12, 2022 — The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between ...

December 12, 2022

News | Cardiovascular Business

Edwards Lifesciences Announces CEO Succession Plan

December 12, 2022 — Edwards Lifesciences Corporation announced that following regular succession planning discussions ...

December 12, 2022

US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza International Trials Unit located in the Lake Zone of Tanzania with the aim of exploring the burden of arrhythmia in adults with and without HIV.

News | Artificial Intelligence

Weill Cornell Medicine partners with Poland-based company Cardiomatics to investigate the relationship between HIV and heart rhythm disorders

December 12, 2022 — US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza ...

December 12, 2022

Dr. Rami Kahwash, director of Ohio State’s Heart and Vascular Research Organization and a professor of clinical medicine in the Ohio State College of Medicine.

News | Cardiovascular Clinical Studies

Ohio State First in World to Participate in Trial Confirming Efficacy of Novel Heart Failure Treatment

December 9, 2022 — The Ohio State University Wexner Medical Center is first in the world to randomize a patient in a ...

December 09, 2022

Cardiac care should follow the patient on a virtual journey and deliver high-fidelity insights to care providers, eliminating the gaps in data transmission

News | Remote Monitoring

With Minutes Between Life and Death, Continuous Remote ECG Monitoring Saves Lives

December 8, 2022 — Heart disease is the number one killer in the U.S., and high-fidelity monitoring is the beginning of ...

December 08, 2022

Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint

News | Cardiovascular Clinical Studies

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint

December 8, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regim ...

December 08, 2022

News | Ultrasound Imaging

Butterfly Announces CEO Transition

December 8, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultraso ...

December 08, 2022